Global Oral Proteins and Peptides Market Expected to Reach USD 3.4 Billion by 2033 - IMARC Group

Global Oral Proteins and Peptides Market Statistics, Outlook and Regional Analysis 2025-2033

The global oral proteins and peptides market size was valued at USD 1.8 Billion in 2024, and it is expected to reach USD 3.4 Billion by 2033, exhibiting a growth rate (CAGR) of 7.13% from 2025 to 2033.

Advancements in drug delivery technologies improve the stability and bioavailability of oral proteins and peptides. This is enhanced by nanotechnology, liposomal carriers, and enteric-coated formulations, which improve the effectiveness of drugs by avoiding enzymatic degradation in the gastrointestinal tract. The increasing prevalence of chronic diseases such as diabetes and gastrointestinal disorders makes patients opt for non-invasive, pain-free treatment options, increasing the demand for oral formulations. Regulatory approvals for innovative oral peptide drugs further spur market growth and push companies to innovate. Advanced biomanufacturing techniques support more targeted therapies with better therapeutic benefits, promoting their use even more broadly. For instance, on February 7, 2024, Johnson & Johnson announced results from its Phase 2b FRONTIER 1 trial of oral peptide JNJ-2113, which targets the IL-23 receptor; it showed substantial effectiveness in moderate-to-severe plaque psoriasis with 79% PASI 75 at the highest dose. It is another promising option to injectables as it is being advanced to Phase 3.

Moreover, growth in the market is expected on account of rising investments in research and development, through which pharmaceutical companies are investigating novel applications beyond traditional indications. Further, there is growing adoption of biologics in oncology, endocrinology, and immunology that presents vast growth potential for the market. The access to innovative drugs through e-commerce and digital health platforms complement the traditional drug distribution channels. Increasing the aging global population with a rapidly growing healthcare expenditure further fuels the requirement for chronic disease management. According to WHO, population aged 60 and older will increase from 1 Billion in 2020 to 1.4 Billion by 2030 and 2.1 Billion by 2050, and the people aged 80 years and above will triple by 2050 to 426 Million. Strategic collaborations between academic institutions, biotech firms, and CROs are enhancing innovation in drug delivery systems. Increased consumer awareness of the convenience and benefits of oral proteins and peptides are reinforcing a global adoption process.

Global Oral Proteins and Peptides Market Statistics, By Region

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share on account of its advanced healthcare infrastructure, strong research and development (R&D) investment, favorable regulatory frameworks, and high prevalence of chronic diseases.

North America Oral Proteins and Peptides Market Trends:

The oral proteins and peptides market in North America is driven by robust research and development (R&D) investments and early adoption of advanced biopharmaceutical technologies. A strong healthcare infrastructure and leading industry players further bolster the market. According to the American Cancer Society, cancer cases in the U.S. are projected to exceed 2 Million in 2024, with over 611,000 deaths, averaging nearly 5,500 diagnoses and 1,600 deaths daily. Chronic diseases such as diabetes and cancer increase demand for advanced therapies. Favorable regulatory frameworks and rising patient awareness of novel drug delivery systems significantly enhance market growth, positioning North America as a leader in oral biopharmaceutical innovation.

Asia-Pacific Oral Proteins and Peptides Market Trends:

Asia-Pacific is experiencing brisk market growth with the up-gradation of health care expenses and rising prevalence of metabolic disorders. China and India are heavily investing in pharmaceutical R&D, supported by government efforts to enhance biotechnology. Demographics with an expanding middle class along with access to better healthcare services drive demand for advanced therapeutic options. Growth in the presence of global pharmaceutical companies also underlines this expansion.

Europe Oral Proteins and Peptides Market Trends:

The growth in biopharmaceutical research funded by government in Europe is heightened in this area as more focus lies in Europe on personalized medicine, making for increased oral proteins and peptides. Growing collaborative interest from pharmaceutical companies with academics regarding oral formulation increases the momentum for innovation. Additionally, a high percentage of old people and massive loads of chronic diseases keep fueling demand for advance drug delivery systems. Regulatory harmonization enhances market access across the European Union and improves growth.

Latin America Oral Proteins and Peptides Market Trends:

The oral proteins and peptides market in Latin America is on a steady growth chart, led by the growing importance of health care awareness with improved access to advanced therapeutics. Health care structures are being improved in terms of infrastructure in countries such as Brazil and Mexico, which have a positive influence on using innovative treatments. The burden of chronic conditions, namely diabetes and obesity, is fueling demand for oral versions of proteins and peptides; collaboration between local and multinationals enhances market options.

Middle East and Africa Oral Proteins and Peptides Market Trends:

Oral proteins and peptides in Middle East and Africa are slowly being on the growth due to improved investments in healthcare and an increase of awareness among the people of advanced treatments in biopharmaceuticals. A growing prevalence of chronic disorders like diabetes in GCC countries boosts up the demand for novel therapies, although economic inequality and lack of effective healthcare infrastructure in some places hinder growth. Improving access to modern treatments, as well as pharmaceutical collaborations, are likely to bolster growth prospects.

Top Companies Leading in the Oral Proteins and Peptides Industry

Some of the leading oral proteins and peptides market companies include Amryt Pharma Plc, AstraZeneca PLC, Biocon Limited, Novo Nordisk A/S, Oramed Ltd, Proxima Concepts Limited, among many others. On September 20, 2024, Novo Nordisk announced phase 2a trial results for monlunabant, an oral CB1 inverse agonist, demonstrating significant weight loss in people with obesity and metabolic syndrome. A 10 mg daily dose resulted in a 7.1 kg weight reduction versus 0.7 kg with placebo, with limited additional benefits at higher doses. Mild to moderate gastrointestinal and neuropsychiatric side effects were dose-dependent, with no serious adverse events. As an innovative oral small molecule, monlunabant highlights Novo Nordisk’s focus on advancing oral therapies for obesity treatment.

Global Oral Proteins and Peptides Market Segmentation Coverage

• Based on drug type, the market is classified into linaclotide, plecanatide, calcitonin, insulin, and octreotide. Linaclotide leads the market share in this segment as it has established efficacy in the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This is a minimally absorbed peptide agonist that provides targeted gastrointestinal benefits with a favorable safety profile. Widespread approval, robust clinical evidence, and strong physician and patient adoption further cement its market leadership.
• On the basis of application, the market has been categorized into gastric and digestive disorders, bone diseases, diabetes, and hormonal disorders, amongst which gastric and digestive disorders dominate the market. The high prevalence is a factor for dominance in oral proteins and peptides, along with increasing demand for effective treatments, making these formulations a vital driver of adoption for peptide-based treatments, such as linaclotide in cases of irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and chronic constipation, targeting significant unmet needs in gastroenterology.